The pathophysiology of menopausal hot flashes has remained largely a mystery until about a decade ago when KNDy neurons were found to be the key triggers of the hot flash. Since then, research and development has been going fullsteam to develop a non-hormonal, receptor-based therapy for the common hot flash. In April 2023 in the journal, Obstetrics and Gynecology (the Green Journal), new safety data will be published on the revolutionary new medication, Fezolinetant. With Phase 3 study results already in print, the FDA is projected to rule on this new medication’s approval potentially in May 2023. In this episode, we will review the fascinating biochemistry of KNDy activity and how this new medication works.
Activity